Article Information
- Received October 17, 2018
- Revision received August 30, 2019
- Accepted September 3, 2019
- Published online September 20, 2019.
Author Information
- Takaya Ishii1,2,
- Mitsuru Ishikawa1,
- Koki Fujimori1,
- Takuji Maeda1,3,
- Itaru Kushima3,4,5,
- Yuko Arioka3,4,
- Daisuke Mori3,
- Yuhki Nakatake6,
- Bun Yamagata7,
- Shintaro Nio7,
- Takahiro A. Kato8,
- Nan Yang9,10,
- Marius Wernig9,
- Shigenobu Kanba8,
- Masaru Mimura7,
- Norio Ozaki3 and
- Hideyuki Okano1
- 1Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan
- 2iPS Cell-Based Drug Discovery, Drug Research Division, Sumitomo Dainippon Pharma. Co., Ltd, Osaka, Osaka 554-0022, Japan
- 3Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Nagoya 466-8550, Japan
- 4Institute for Advanced Research, Nagoya University, Aichi, Nagoya 466-8550, Japan
- 5Medical Genomics Center, Nagoya University Hospital, Aichi, Nagoya 466-8550, Japan
- 6Department of Systems Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan
- 7Department of Neuropsychiatry, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan
- 8Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka 812-8582, Japan
- 9Institute for Stem Cell Biology and Regenerative Medicine and Department of Pathology, Stanford University School of Medicine, Stanford, California 94305
- 10Department of Neuroscience, Friedman Brian Institute, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York 10029
- Correspondence should be addressed to Hideyuki Okano at hidokano{at}a2.keo.jp.
Author contributions
Author contributions: T.I., M.I., D.M., S.K., M.M., N.O., and H.O. designed research; T.I., M.I., K.F., T.M., I.K., and Y.A. performed research; T.I. and K.F. analyzed data; T.I., K.F., I.K., T.A.K., and H.O. wrote the paper; Y.N., B.Y., S.N., T.A.K., N.Y., and M.W. contributed unpublished reagents/analytic tools.
Disclosures
H.O. is a founding scientist of SanBio Co. Ltd. and K Pharma Inc. T.I. and K.F are employed by Sumitomo Dainippon Pharma Co., Ltd. H.O. and N.O. received research funding from Sumitomo Dainippon Pharma Co., Ltd. The authors declare no other competing financial interests.
The work was supported by the Japan Agency for Medical Research and Development under Grants JP16bk0104016, JP18dm0107087, JP18dm0207005, JP19dm0207075h0001, JP18dk0307081, JP18dm0107095, JP19bm0804003h0003, JP19bm0804014h0103, and JP17dk0307047; and Japan Society for the Promotion of Science KAKENHI Grants JP1710083, JP26830018, JP18H04042, and JP16H02666.
Funding
Japan Agency for Medical Research and Development (AMED)
JP16bk0104016; JP18dm0107087; JP18dm0207005; JP18dk0307081; JP19dm0207075h0001; JP18dm0107095; JP17dk0307047; JP17bm0804003h0001; JP18bm0804014h0102Japan Society for the Promotion of Science (JSPS)
JP1710083; JP26830018; JP18H04042; JP16H02666
Other Version
- You are viewing the most recent version of this article.
- previous version (September 20, 2019).
Article usage
In this issue
